Cannabinoid WIN 55,212-2 Regulates TRPV1 Phosphorylation in

Embed Size (px)

Text of Cannabinoid WIN 55,212-2 Regulates TRPV1 Phosphorylation in

  • Cannabinoid WIN 55,212-2 Regulates TRPV1 Phosphorylationin Sensory Neurons*Received for publication, April 5, 2006, and in revised form, August 31, 2006 Published, JBC Papers in Press, September 5, 2006, DOI 10.1074/jbc.M603220200

    Nathaniel A. Jeske, Amol M. Patwardhan, Nikita Gamper1, Theodore J. Price2, Armen N. Akopian,and Kenneth M. Hargreaves3

    From the Departments of Endodontics, Pharmacology, and Physiology, University of Texas Health Science Center,San Antonio, Texas 78229-3900

    Cannabinoids are known tohavemultiple sites of action in thenociceptive system, leading to reducedpain sensation.However,the peripheral mechanism(s) by which this phenomenon occursremains an issue that has yet to be resolved. Because phospho-rylation of TRPV1 (transient receptor potential subtype V1)plays a key role in the induction of thermal hyperalgesia ininflammatory pain models, we evaluated whether the cannabi-noid agonist WIN 55,212-2 (WIN) regulates the phosphoryla-tion state of TRPV1. Here, we show that treatment of primaryrat trigeminal ganglion cultures withWIN led to dephosphoryl-ationofTRPV1, specifically at threonine residues.UtilizingChi-nese hamster ovary cell lines, we demonstrate that Thr144 andThr370 were dephosphorylated, leading to desensitization of theTRPV1 receptor. This post-translational modification occurredthrough activation of the phosphatase calcineurin (proteinphosphatase 2B) following WIN treatment. Furthermore,knockdown of TRPA1 (transient receptor potential subtype A1)expression in sensory neurons by specific small interfering RNAabolished the WIN effect on TRPV1 dephosphorylation, sug-gesting that WIN acts through TRPA1. We also confirm theimportance of TRPA1 in WIN-induced dephosphorylation ofTRPV1 in Chinese hamster ovary cells through targeted expres-sion of one or both receptor channels. These results imply thatthe cannabinoidWINmodulates the sensitivity of sensory neu-rons to TRPV1 activation by altering receptor phosphorylation.In addition, our data could serve as a useful strategy in deter-mining the potential use of certain cannabinoids as peripheralanalgesics.

    Cannabinoids have been shown to exert anti-inflammatoryand anti-hyperalgesic effects via peripheral site(s) of action inseveral painmodels (15). These effects are thought to bemedi-

    ated by cannabinoid type 1 (CB1)4 and/or 2 (CB2) receptoractivation, both peripherally and centrally (47). Cannabinoidscould exert their effects by acting on CB1/CB2 receptorslocated on sensory neurons and/or other peripheral cells influ-encing sensory neuronal function (8). However, there is a510% co-localization of metabotropic CB1/CB2 receptorswith nociceptive neuronal markers such as TRPV1 (transientreceptor potential subtype V1) and calcitonin gene-relatedpeptide in trigeminal and dorsal root ganglion neurons (911),suggesting that cannabinoids could act on nociceptors throughnon-CB1/CB2 receptor mechanism(s). Certain cannabinoidshave been shown to activate channels such asTRPV1, includingarachidonyl-2-chloroethylamide (ACEA) (12), N-arachido-noyldopamine (13), and anandamide (14), as well as TRPA1(transient receptor potential subtype A1), including 9-tetra-hydrocannabinol (15). In addition, the synthetic cannabinoidR()-WIN 55,212-2 (WIN) has demonstrated non-CB1/CB2receptor activities in trigeminal ganglia (11). The results fromthese studies suggest that cannabinoids may activate calciumchannel function similar to non-cannabinoid transient recep-tor potential agonists, including the ability to desensitize chan-nel activity.The transient receptor potential channel TRPV1 is a nonse-

    lective cation channel that responds to various stimuli, includ-ing heat (42 C), protons, capsaicin, and certain cannabinoids(14, 1619). TRPV1 is principally expressed in C-type nocicep-tive afferent neurons throughout the periphery and has beendemonstrated to play a critical role in the induction of thermalhyperalgesia in inflammatory pain models (16, 20, 21). There isgeneral agreement that TRPV1 controls nociceptor sensitiza-tion to thermally noxious stimuli by inflammation-inducedpost-translational modifications, including phosphorylation(22, 23). Conversely, dephosphorylation of TRPV1 can lead topharmacological desensitization of its activation by chemicalstimuli (2426).The desensitizing effect of channel activation has been uti-

    lized clinically to reduce the afferent transmission of painfulstimuli (27). Repeated activation of TRPV1 by chemical stimuliresults in calcium-dependent desensitization of the receptor

    * This work was supported by National Institutes of Health Grants F32-DE016500 (to N. A. J.), R21-DE014928 (to A. N. A.), and R01-DA19585 (toK. M. H.). The costs of publication of this article were defrayed in part by thepayment of page charges. This article must therefore be hereby markedadvertisement in accordance with 18 U.S.C. Section 1734 solely to indi-cate this fact.

    1 Present address: Inst. of Membrane and System Biology, University of Leeds,Leeds LS2 9JT, UK.

    2 Present address: Dept. of Anesthesia, McGill University, Montreal, QuebecH3G 1Y6, Canada.

    3 To whom correspondence should be addressed: Dept. of Endodontics, Uni-versity of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX78229-3900. Tel.: 210-567-3388; Fax: 210-567-3389; E-mail: Hargreaves@UTHSCSA.edu.

    4 The abbreviations used are: CB1, cannabinoid type 1; CB2, cannabinoid type2; ACEA, arachidonyl-2-chloroethylamide; WIN, WIN 55,212-2; CHO, Chi-nese hamster ovary; TG, trigeminal ganglion; ANOVA, analysis of variance;PBS, phosphate-buffered saline; siRNA, small interfering RNA; TRITC, tetra-methylrhodamine isothiocyanate; HPLC, high performance liquid chroma-tography; GFP, green fluorescent protein; PLC, phospholipase C; PHD,pleckstrin homology domain; ICAP, inward capsaicin current.

    THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 43, pp. 32879 32890, October 27, 2006 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

    OCTOBER 27, 2006 VOLUME 281 NUMBER 43 JOURNAL OF BIOLOGICAL CHEMISTRY 32879

    by guest on March 29, 2018

    http://ww

    w.jbc.org/

    Dow

    nloaded from

    http://www.jbc.org/

  • (24). Specifically, capsaicin has been shown to lead to dephos-phorylation of TRPV1, thereby desensitizing the receptor (25).As the receptor ion channel is activated, calcium ions enter thecell and stimulate calcium-dependent signaling mechanisms,including calcineurin-dependent dephosphorylation of TRPV1(26). Coincidently, calcium-dependent sensitization of thereceptor canalsooccur throughactivationofCa2/calmodulin-dependent kinase II (28) and protein kinase C (29). The balancebetween calcium-stimulated kinase and phosphatase activitiesresults in a tightly regulated system responsible for modulatingTRPV1 activity.In this study, we examinedwhether certain cannabinoids can

    regulate the phosphorylation state of TRPV1, resulting inmod-ulation of receptor activities. Furthermore, we demonstratethat treatment with the cannabinoid WIN results not only incalcineurin activation and dephosphorylation of the TRPV1receptor at Thr144 and Thr370, but does so in amanner depend-ent upon TRPA1 coexpression.

    EXPERIMENTAL PROCEDURES

    Cell Culture and Transfection of cDNATrigeminal gangliawere removed bilaterally frommale Sprague-Dawley rats (200250 g; Charles River Laboratories,Wilmington,MA) and disso-ciated by treatmentwith collagenase (Worthington) for 30min,followed by treatment with trypsin (Sigma) for 15 min andDNase I (Roche Applied Science) for 5 min. Cells were centri-fuged and resuspended between each treatment with Pasteurpipettes. Cells were centrifuged; aspirated; resuspended in Dul-beccos modified Eagles medium (Invitrogen) with 10% fetalbovine serum (Invitrogen), 250 ng/ml nerve growth factor(Harlan SpragueDawley, Inc., Indianapolis, IN), 1% 5-fluorode-oxyuridine (Sigma), 1% penicillin/streptomycin (Invitrogen), and1% L-glutamine (Sigma); and then plated onto plates coatedwith poly-D-lysine. Cultures were maintained at 37 C and 5%CO2 and grown in 10-cm plates for 57 days for phosphoryla-tion experiments. Chinese hamster ovary (CHO) cells were uti-lized for heterologous expression of cDNA constructs. Theywere maintained at 37 C and 5% CO2 and transfected usingLipofectamine 2000 (Invitrogen) following the manufacturersinstructions. Trigeminal ganglion (TG) neurons were trans-fected using a PDS-1000/He biolistic system (Bio-Rad) accord-ing to the manufacturers instructions.cDNA Constructs and Site-directed MutagenesisRat

    TRPV1 cDNAwas kindly provided byDr. David Julius (Univer-sity of California, San Francisco, CA), andmouseTRPA1 cDNAwas kindly provided by Dr. Ardem Patapoutian (ScrippsResearch Institute, SanDiego, CA). The entire coding sequenceof mouse TRPA1 (30), apart from the start codon, was used togenerate aMyc-taggedmouse TRPA1 construct in pCMV-Myc(Clontech). pEGFP-N1 cDNA was purchased from Clontech,and bradykinin type 2 and muscarinic type 1 receptor cDNAswere purchased from the University of Missouri cDNAResource Center (Rolla, MO). Site-directed mutagenesis wasperformedusing theQuikChangeXL site-directedmutagenesiskit (Stratagene, La Jolla, CA) following the manufacturersinstructions. Rat TRPV1(T144A) cDNAwas kindly provided byDr. Carla Nau (Friedrich-Alexander University, Erlangen, Ger-many). To create rat TRPV1(T370A), the forward primer used

    was 5-CCAGGAAGTTCGCCGAATGGGCCTATGGG. Tocreate rat TRPV1(T704A), the forward primer used was 5-GCAGAGAGCCATCGCCATCCTGGATACAG. All muta-tions were confirmed by sequencing at the Advanced NucleicAcids Core Facility of the University of Texas Health ScienceCenter at San Antonio.Immunoprecipitation and Western Blot AnalysisFor each

    experimental condition, cells were treated with the appropriatecompounds and harvested as described previo